Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stress Disorders, Post-Traumatic

Conditions

Stress Disorders, Post-Traumatic

Trial Timeline

Jan 26, 2017 → Nov 12, 2018

About Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo

Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo is a phase 2 stage product being developed by Lundbeck for Stress Disorders, Post-Traumatic. The current trial status is completed. This product is registered under clinical trial identifier NCT03033069. Target conditions include Stress Disorders, Post-Traumatic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03033069Phase 2Completed

Competing Products

20 competing products in Stress Disorders, Post-Traumatic

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
agenT-797MiNK TherapeuticsPhase 1
25
Thermal stress and performance without a pre-cooling protocolPetros PharmaceuticalsPre-clinical
15
solifenacinAstellas PharmaApproved
85
SivelestatEli LillyPhase 1/2
41
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine hydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
duloxetine + PlaceboEli LillyPhase 2
52
Exenatide + InsulinEli LillyPhase 2/3
65
DuloxetineEli LillyPhase 3
77
duloxetine HClEli LillyApproved
85
Orforglipron + PlaceboEli LillyPhase 3
77
Duloxetine hydrochloride + placeboEli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77